This company has been marked as potentially delisted and may not be actively trading. Merrimack Pharmaceuticals (MACK) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock MACK Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Merrimack Pharma Stock Price HistoryJune 4, 2025 | investing.comCollege football connection: Easton’s Hutchison posts 2 TDs in F&M victorySeptember 25, 2024 | msn.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | investorplace.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases Dividend to $15.10 Per ShareMay 16, 2024 | marketbeat.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | msn.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMACK Merrimack Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsApril 3, 2024 | finance.yahoo.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 27, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19March 26, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short InterestMarch 18, 2024 | marketbeat.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | msn.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 8, 2024 | investorplace.comMerrimack Reports Full Year 2023 Financial ResultsMarch 7, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.93March 5, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 22, 2024 | benzinga.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 17, 2024 | finance.yahoo.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 15, 2024 | markets.businessinsider.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 14, 2024 | finance.yahoo.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | msn.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | marketwatch.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.65February 13, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.55January 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.comJanuary 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded by StockNews.comJanuary 23, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Eric Andersen Purchases 857 SharesDecember 28, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to Hold at StockNews.comDecember 27, 2023 | marketbeat.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 12, 2023 | msn.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowDecember 10, 2023 | finance.yahoo.comMerrimack Pharmaceuticals Inc MACKNovember 10, 2023 | morningstar.comMMerrimack Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 24, 2023 | stockhouse.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmOctober 20, 2023 | theglobeandmail.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 15, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptAugust 13, 2023 | insidermonkey.comMerrimack Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comPharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finanznachrichten.dePharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finance.yahoo.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered by StockNews.comJuly 7, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded to "Sell" at StockNews.comJune 23, 2023 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is 22Nw LP's 6th Largest PositionMay 26, 2023 | marketbeat.comShort Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases By 6.7%May 2, 2023 | marketbeat.com Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MACK Media Mentions By Week MACK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MACK News Sentiment▼0.920.94▲Average Medical News Sentiment MACK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MACK Articles This Week▼00▲MACK Articles Average Week Get the Latest News and Ratings for MACK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Merrimack Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GERN News MYGN News RIGL News VSTM News XOMA News EBS News LXRX News VNDA News CBIO News CDXS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MACK) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merrimack Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MACK Stock Alerts